1. Home
  2. CAC vs FTRE Comparison

CAC vs FTRE Comparison

Compare CAC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$49.09

Market Cap

857.1M

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$15.34

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
FTRE
Founded
1875
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.1M
829.3M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
CAC
FTRE
Price
$49.09
$15.34
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$47.00
$14.06
AVG Volume (30 Days)
79.4K
1.4M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
3.51%
N/A
EPS Growth
6.08
N/A
EPS
1.29
N/A
Revenue
$41,739,000.00
$2,723,400,000.00
Revenue This Year
$19.15
N/A
Revenue Next Year
$6.05
$3.09
P/E Ratio
$12.67
N/A
Revenue Growth
16.96
1.00
52 Week Low
$35.00
$3.97
52 Week High
$53.71
$18.67

Technical Indicators

Market Signals
Indicator
CAC
FTRE
Relative Strength Index (RSI) 51.88 81.98
Support Level $47.25 $8.85
Resistance Level $51.57 $18.26
Average True Range (ATR) 1.47 0.89
MACD -0.17 0.61
Stochastic Oscillator 31.89 91.00

Price Performance

Historical Comparison
CAC
FTRE

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: